YD Bio (YDES) Stock Price

YD Bio Price

CLOSED
6.38
​
Market closed

Revenue has compounded at 30.6% per year over the past 2 years to 596,817.00 USD. Earnings per share have declined at 84.0% per year over the last 2 years. YD Bio's net margin stands at -1,392.6%, down from 3.9% several years earlier.

YD Bio stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio business model & stock analysis

YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives.

Frequently asked questions about YD Bio

Converted at the current exchange rate, the YD Bio share trades at 5.69 EUR (6.38 USD).

The revenue cannot currently be calculated for YD Bio.

The profit cannot currently be calculated for YD Bio.

The P/E ratio cannot be calculated for YD Bio at the moment.

The P/S cannot be calculated for YD Bio currently.

The Eulerpool Quality Score for YD Bio is 2/10.

The ISIN of YD Bio is KYG983011076. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of YD Bio is YDES. The ticker symbol is used to trade YD Bio shares on the stock exchange.

Fair ValueTerminal
6.70 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
USD
Initial public offering
Aug 29, 2025
ISIN
KYG983011076
Cusip
G98301107
Market capitalization
450.06 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
68.29
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
291.74 %
Last updated Oct 16, 2026, 2:35 PM

YD Bio Peer Group

All fundamentals and in-depth analysis of YD Bio

Our stock analysis for YD Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of YD Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.